Compare Equinix Inc (EQIX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Zimmer Biomet Holdings Inc — how do they compare? Equinix Inc trades at $1,020.74 (market cap $99.77B), while Zimmer Biomet Holdings Inc trades at $89.08 (market cap $16.95B). The key difference: Equinix Inc is far larger — about 5.9× Zimmer Biomet Holdings Inc's market cap, and Equinix Inc pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EQIX | ZBH | |
|---|---|---|
Market Cap | $99.77B | $16.95B |
Volume | 480,425 | 2,505,240 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $103.98 |
52-Week Low | $726.09 | $79.58 |
Typical Hold Time | 110 Days | 89 Days |
Enterprise Value | $120.90B | $24.02B |
Dividend Yield | 2.04% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,016.30, down 1.5% on the day, amid a bullish technical trend and strong analyst support. The stock shows robust revenue growth, with 2025 revenue reaching $9.22 billion and net income margin improving to 14.64%. Recent news highlights accelerating AI-driven demand for data centers, with the company planning $5–7 billion in annual investments. However, high valuation ratios like a P/E of 65.07 and negative net cash flow in 2025 pose concerns.
The outlook for EQIX is positive due to AI infrastructure demand and solid earnings growth, but risks include elevated debt levels and capital expenditure pressures. Wall Street consensus is strongly bullish with a $1,250 price target, though investors should weigh valuation against execution risks in a competitive sector.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
